Faron Pharmaceuticals Oy (FARN) - Total Assets
Based on the latest financial reports, Faron Pharmaceuticals Oy (FARN) holds total assets worth GBX16.20 Million GBX (≈ $1.97K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check FARN capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Faron Pharmaceuticals Oy - Total Assets Trend (2012–2024)
This chart illustrates how Faron Pharmaceuticals Oy's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Faron Pharmaceuticals Oy to see how much of total assets are deployed in long-term investments.
Faron Pharmaceuticals Oy - Asset Composition Analysis
Current Asset Composition (December 2024)
Faron Pharmaceuticals Oy's total assets of GBX16.20 Million consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 75.9% |
| Accounts Receivable | GBX201.00K | 1.6% |
| Inventory | GBX-201.00K | -1.6% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX1.11 Million | 8.9% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Faron Pharmaceuticals Oy's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Faron Pharmaceuticals Oy worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Faron Pharmaceuticals Oy's current assets represent 88.4% of total assets in 2024, an increase from 44.4% in 2012.
- Cash Position: Cash and equivalents constituted 75.9% of total assets in 2024, up from 0.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 55.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 8.9% of total assets.
Faron Pharmaceuticals Oy Competitors by Total Assets
Key competitors of Faron Pharmaceuticals Oy based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Faron Pharmaceuticals Oy - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 1.45 | 2.98 |
| Quick Ratio | 1.89 | 1.45 | 2.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX6.98 Million | GBX10.47 Million | GBX8.79 Million |
Faron Pharmaceuticals Oy - Advanced Valuation Insights
This section examines the relationship between Faron Pharmaceuticals Oy's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 165.73 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 22.5% |
| Total Assets | GBX12.52 Million |
| Market Capitalization | $602.85K USD |
Valuation Analysis
Below Book Valuation: The market values Faron Pharmaceuticals Oy's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Faron Pharmaceuticals Oy's assets grew by 22.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Faron Pharmaceuticals Oy (2012–2024)
The table below shows the annual total assets of Faron Pharmaceuticals Oy from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX12.52 Million ≈ $1.52K |
+22.51% |
| 2023-12-31 | GBX10.22 Million ≈ $1.24K |
-9.32% |
| 2022-12-31 | GBX11.27 Million ≈ $1.37K |
-14.50% |
| 2021-12-31 | GBX13.18 Million ≈ $1.60K |
+57.55% |
| 2020-12-31 | GBX8.37 Million ≈ $1.02K |
-18.04% |
| 2019-12-31 | GBX10.21 Million ≈ $1.24K |
+27.58% |
| 2018-12-31 | GBX8.00 Million ≈ $973.61 |
-46.25% |
| 2017-12-31 | GBX14.89 Million ≈ $1.81K |
-13.88% |
| 2016-12-31 | GBX17.29 Million ≈ $2.10K |
+16.64% |
| 2015-12-31 | GBX14.82 Million ≈ $1.80K |
+584.57% |
| 2014-12-31 | GBX2.17 Million ≈ $263.42 |
-3.22% |
| 2013-12-31 | GBX2.24 Million ≈ $272.18 |
+15.55% |
| 2012-12-31 | GBX1.94 Million ≈ $235.56 |
-- |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more